Cargando…
Time course of glatiramer acetate efficacy in patients with RRMS in the GALA study
OBJECTIVE: To determine the time to efficacy onset of glatiramer acetate (GA) 40 mg/mL 3-times-weekly formulation (GA40). METHODS: This post hoc analysis of data from the 1-year, double-blind, placebo-controlled phase of the Glatiramer Acetate Low-Frequency Administration study (NCT01067521) of GA40...
Autores principales: | Davis, Mat D., Ashtamker, Natalia, Steinerman, Joshua R., Knappertz, Volker |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5299631/ https://www.ncbi.nlm.nih.gov/pubmed/28210662 http://dx.doi.org/10.1212/NXI.0000000000000327 |
Ejemplares similares
-
Long-term efficacy and safety of three times weekly dosing regimen of glatiramer acetate in relapsing multiple sclerosis patients: Seven-year results of the Glatiramer Acetate Low-frequency Administration (GALA) open-label extension study
por: Rieckmann, Peter, et al.
Publicado: (2021) -
Once‐daily glatiramer acetate decreases magnetic resonance imaging disease activity in Japanese patients with relapsing–remitting multiple sclerosis
por: Yamamura, Takashi, et al.
Publicado: (2017) -
The Effect of Three Times a Week Glatiramer Acetate on Cerebral T1 Hypointense Lesions in Relapsing‐Remitting Multiple Sclerosis
por: Zivadinov, Robert, et al.
Publicado: (2015) -
Preparation, characterization and in-vivo efficacy study of glatiramer acetate (GA)-hydrogel-microparticles as novel drug delivery system for GA in RRMS
por: Hadidi, Naghmeh, et al.
Publicado: (2022) -
Follow-on glatiramer acetate
por: Cohen, Jeffrey A., et al.
Publicado: (2018)